Hangzhou Shuolin Biotechnology Co., Ltd. was founded in November 2022. We focus on researching, developing, manufacturing, and marketing characteristic APIs and key pharmaceutical intermediates. We also offer customized processing and R&D services, as well as drug manufacturing services to cooperative partners. Our products are exported to Southeast Asia, Middle East, Africa and other regions.
Our products categories, including renal anemia raw materials, cardio-cerebrovascular, antibacterial, immune, and anti-tumor. The developed products have complex chiral structures, making research and development challenging due to high technical barriers and unique production technology. Our advanced technological innovation and R&D rely on high investment that over 20% of total income each year.
Shuolin focuses on the health industry, in pursuit of quality and innovation. Our purpose is to serve healthy industries and be a reliable partner to our customers. We aim to create a world-class R&D innovation and service system with the ability to create new products and generic drug technology. We are guided by principle of 'win-win' and aligned with the requirements of the national innovation and development strategy. We are expanding sales network and open up high-end normative markets such as Japan, South Korea, and Europe. Our goal is to become a globally competitive enterprise.
